Claims for Patent: 9,220,747

Summary for Patent: 9,220,747

Title:	Methods using desmopressin acetate in orodispersible form
Abstract:	Described are orodispersible solid dosage forms of desmopressin or a pharmaceutically acceptable salt thereof useful for treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus. The dosage forms disintegrate in the mouth within 10 seconds and provide good desmopressin bioavailability.
Inventor(s):	Nilsson; Anders (Lund, SE), Lindner; Hans (Berlin, DE), Wittendorff; Jcrgen (Hvidovre, DK)
Assignee:	FERRING B.V. (Hoofddorp, NL)
Application Number:	14/326,939
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,220,747
Patent Claims:	1. A method of treating a disease or condition selected from the group consisting of incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus, comprising administering to a subject in need thereof an effective and generally non-toxic amount of desmopressin acetate in an orodispersible solid dosage form, wherein the dosage form (A) disintegrates in the mouth within 10 seconds and (B) comprises an amount of desmopressin acetate, measured as the free base, of from 0.5 .mu.g to 75 .mu.g, and wherein the method results in a desmopressin bioavailability of from greater than 0.1% to about 0.38%. 2. The method of claim 1, wherein the method results in a desmopressin bioavailability of about 0.23% to about 0.38%. 3. The method of claim 2, wherein the method results in a desmopressin bioavailability of about 0.30%. 4. The method of claim 1, wherein the dosage form comprises an amount of desmopressin acetate, measured as the free base, of from 1 .mu.g to 50 .mu.g. 5. The method of claim 1, wherein the dosage form further comprises an open matrix network carrying the desmopressin acetate, the open matrix network being comprised of a water-soluble or water-dispersible carrier material that is inert towards desmopressin. 6. The method of claim 5, wherein the open matrix network comprises gelatin. 7. The method of claim 6, wherein the gelatin is fish gelatin. 8. The method of claim 7, wherein the fish gelatin is non-gelling. 9. The method of claim 1, wherein the dosage form further comprises citric acid. 10. The method of claim 1, wherein the disease or condition is primary nocturnal enuresis (PNE). 11. The method of claim 1, wherein the disease or condition is nocturia. 12. The method of claim 1, wherein the dosage form disintegrates in the mouth within 5 seconds. 13. The method of claim 1, wherein the dosage form disintegrates in the mouth within 2 seconds. 14. The method of claim 1, wherein the dosage form is administered once per day. 15. The method of claim 1, wherein the dosage form is administered twice per day. 16. The method of claim 1, wherein the method results in a desmopressin bioavailability of from greater than 0.1% to 0.38%. 17. The method of claim 1, wherein the method results in a desmopressin bioavailability of from 0.23% to 0.38%. 18. The method of claim 1, wherein the method results in a desmopressin bioavailability of 0.30%.